Immune consequences of anti-angiogenic therapy in renal cell carcinoma

Klaudia K. Brodaczewska; Cezary Szczylik; Claudine Kieda

doi:10.5114/wo.2018.73878

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Bieżący numer Archiwum Współczesna Onkologia

NOWOŚĆ

Portal dla onkologów!

www.eonkologia.pl

Wyszukiwanie

1/2018

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Artykuł przeglądowy

Immune consequences of anti-angiogenic therapy in renal cell carcinoma

Klaudia K. Brodaczewska

,

Cezary Szczylik

,

Claudine Kieda

DOI: https://doi.org/10.5114/wo.2018.73878

Data publikacji online: 2018/03/08

Pełna treść artykułu Pobierz cytowanie

Metryki PlumX:

Current therapies of renal cell carcinoma (RCC), a highly vascularised tumour, mostly rely on anti-angiogenic treatment options. These include tyrosine kinase inhibitors (TKIs) and anti-VEGF monoclonal antibodies. Although these strategies aim at restraining vascularisation to control tumour growth, the effects of such therapies are much wider, as affecting the vessel structure deeply modifies the microenvironment of the tumour mass. The aim of this review is to provide an overview of current knowledge on the global effects of anti-angiogenic treatment, mostly TKIs, on the shaping of the immune component of the RCC microenvironment. The data supporting the modification of immunity by anti-angiogenic therapies are collected to reveal the potential of angiogenesis modulation as a strategy for the adjuvant anti-cancer approach in immunotherapy.

Immune consequences of anti-angiogenic therapy in renal cell carcinoma

Klaudia K. Brodaczewska , Cezary Szczylik , Claudine Kieda

Klaudia K. Brodaczewska

,

Cezary Szczylik

,

Claudine Kieda